Johnson & Johnson ($JNJ) and Pharmacyclics ($PCYC) nabbed the FDA's new breakthrough designation for their cancer drug ibrutinib, a promising late-stage therapy that will be put in the hands of regulators later this year. Report
Bloomberg Businessweek outlines how Varian Medical, manufacturer of medical devices and software for treating cancer and other medical conditions, introduced a lean, paperless product-design process, automated manufacturing and quality management, and improved collaboration from engineering and production. Download the case study today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!